RESUMEN
A 7 year-old twin girl with hypophosphataemic rickets was evaluated for a recent onset of mild strabismus.She was a homozygous twin sister with hypophosphataemic rickets diagnosed at the age of 2 years, with a mutation in intron 21 of the PHEX gene, which was also present in her sister.The girls' clinical histories were remarkable for an important lower limb varus that progressively improved after starting phosphate supplementation with a galenical solution (Joulies solution 1 mmol phosphate/ml) and vitamin D 1,25 OH.During the examinations, both girls were in good general condition. Physical examinations were unremarkable, except for tibial varus, bilateral fifth finger clinodactyly and bilateral syndactyly of the third and fourth foot fingers. No major head shape abnormalities were noticeable except for a high forehead.One patient presented with a slight strabismus, normal isochoric isocyclic and reactive pupils, no signs of cranial nerve deficit, and no alterations in the rest of the neurological examination. An ophthalmological evaluation showed bilateral papilloedema. A cerebral MRI scan was then performed, suspecting elevated intracranial pressure (figure 1). The same examination was performed on the asymptomatic sister which also demonstrated papilloedema with similar findings on cranial MRI too.
Asunto(s)
Raquitismo Hipofosfatémico Familiar , Papiledema , Raquitismo Hipofosfatémico , Estrabismo , Niño , Preescolar , Potenciales Evocados Visuales , Raquitismo Hipofosfatémico Familiar/diagnóstico , Raquitismo Hipofosfatémico Familiar/genética , Raquitismo Hipofosfatémico Familiar/terapia , Femenino , Humanos , Masculino , Fosfatos , Raquitismo Hipofosfatémico/diagnóstico , Raquitismo Hipofosfatémico/genética , Raquitismo Hipofosfatémico/terapiaRESUMEN
Fibroblast growth factor-23 (FGF23) is central to phosphate homeostasis. The author examined if blood levels of FGF23 allow discrimination of classic hypophosphatemic rickets from other causes of non-nutritional rickets with hypophosphatemia. Forty-two children (median age: 102 mo) with non-nutritional rickets and hypophosphatemia were clinically classified as having distal renal tubular acidosis (RTA, n = 12), Fanconi syndrome (n = 8), classic hypophosphatemic rickets (n = 11), vitamin D dependent rickets (n = 7) and Dent disease (n = 4). Median blood FGF23 (measured by C-terminal ELISA) concentrations were similar in all groups (P = 0.24). These levels did not correlate with phosphate, tubular maximum for phosphate, calcium, 25-hydroxyvitamin D, creatinine, and parathormone levels. Patients with distal RTA showed variable degree of proximal tubular dysfunction that resolved following alkali supplements. Blood FGF23 levels did not satisfactorily differentiate classic hypophosphatemic rickets from other causes of hypophosphatemic rickets.
Asunto(s)
Factores de Crecimiento de Fibroblastos/sangre , Raquitismo Hipofosfatémico/sangre , Acidosis Tubular Renal/sangre , Acidosis Tubular Renal/diagnóstico , Niño , Enfermedad de Dent/sangre , Enfermedad de Dent/diagnóstico , Diagnóstico Diferencial , Ensayo de Inmunoadsorción Enzimática , Síndrome de Fanconi/sangre , Síndrome de Fanconi/diagnóstico , Femenino , Factor-23 de Crecimiento de Fibroblastos , Humanos , Masculino , Raquitismo/sangre , Raquitismo/diagnóstico , Raquitismo Hipofosfatémico/diagnósticoRESUMEN
Hypophosphatemic rickets, mostly of the X-linked dominant form caused by pathogenic variants of the PHEX gene, poses therapeutic challenges with consequences for growth and bone development and portends a high risk of fractions and poor bone healing, dental problems and nephrolithiasis/nephrocalcinosis. Conventional treatment consists of PO4 supplements and calcitriol requiring monitoring for treatment-emergent adverse effects. FGF23 measurement, where available, has implications for the differential diagnosis of hypophosphatemia syndromes and, potentially, treatment monitoring. Newer therapeutic modalities include calcium sensing receptor modulation (cinacalcet) and biological molecules targeting FGF23 or its receptors. Their long-term effects must be compared with those of conventional treatments.
Asunto(s)
Raquitismo Hipofosfatémico/diagnóstico , Raquitismo Hipofosfatémico/tratamiento farmacológico , Raquitismo Hipofosfatémico/genética , Calcimiméticos/uso terapéutico , Niño , Diagnóstico Diferencial , Factor-23 de Crecimiento de Fibroblastos , Hormona del Crecimiento/uso terapéutico , Humanos , Mutación , Fosfatos/uso terapéutico , Vitamina D/uso terapéuticoRESUMEN
The association of hypophosphataemic rickets with verrucous epidermal naevus (EN) and elevated fibroblast growth factor 23 levels is known as cutaneous-skeletal hypophosphataemia syndrome (CSHS), and can be caused by somatic activating mutations in RAS genes. We report a unique patient with CSHS associated with giant congenital melanocytic naevus (CMN), neurocutaneous melanosis and EN syndrome, manifesting as facial linear sebaceous naevus, developmental delay and ocular dermoids. An activating mutation Q61R in the NRAS gene was found in affected skin and ocular tissue but not blood, implying that the disparate manifestations are due to a multilineage activating mutation (mosaic RASopathy). We speculate on the apparently rare association of CSHS with CMN compared with EN. We also report the favourable outcome of this patient at the age of 8 years after extensive neonatal curettage of the giant CMN and use of vitamin D and phosphate supplementation.
Asunto(s)
ADN de Neoplasias/genética , GTP Fosfohidrolasas/genética , Proteínas de la Membrana/genética , Mosaicismo , Nevo Pigmentado/genética , Nevo/genética , Raquitismo Hipofosfatémico/genética , Neoplasias Cutáneas/genética , Piel/patología , Preescolar , Análisis Mutacional de ADN , GTP Fosfohidrolasas/metabolismo , Humanos , Masculino , Proteínas de la Membrana/metabolismo , Mutación , Nevo/diagnóstico , Nevo/metabolismo , Nevo Pigmentado/diagnóstico , Nevo Pigmentado/metabolismo , Raquitismo Hipofosfatémico/congénito , Raquitismo Hipofosfatémico/diagnóstico , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/metabolismoRESUMEN
CONTEXT: Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is an autosomal recessive disease caused by biallelic mutations in the vitamin D receptor (VDR) gene. No patients have been reported with uniparental disomy (UPD). OBJECTIVE: Using genome-wide single nucleotide polymorphism (SNP) array to confirm whether HVDRR was caused by UPD of chromosome 12. MATERIALS AND METHODS: A 2-year-old girl with alopecia and short stature and without any family history of consanguinity was diagnosed with HVDRR by typical laboratory data findings and clinical features of rickets. Sequence analysis of VDR was performed, and the origin of the homozygous mutation was investigated by target SNP sequencing, short tandem repeat analysis, and genome-wide SNP array. RESULTS: The patient had a homozygous p.Arg73Ter nonsense mutation. Her mother was heterozygous for the mutation, but her father was negative. We excluded gross deletion of the father's allele or paternal discordance. Genome-wide SNP array of the family (the patient and her parents) showed complete maternal isodisomy of chromosome 12. She was successfully treated with high-dose oral calcium. CONCLUSIONS: This is the first report of HVDRR caused by UPD, and the third case of complete UPD of chromosome 12, in the published literature. Genome-wide SNP array was useful for detecting isodisomy and the parental origin of the allele. Comprehensive examination of the homozygous state is essential for accurate genetic counseling of recurrence risk and appropriate monitoring for other chromosome 12 related disorders. Furthermore, oral calcium therapy was effective as an initial treatment for rickets in this instance.
Asunto(s)
Cromosomas Humanos Par 12 , Polimorfismo de Nucleótido Simple , Raquitismo Hipofosfatémico/diagnóstico , Raquitismo Hipofosfatémico/genética , Disomía Uniparental/genética , Vitamina D/análogos & derivados , Administración Oral , Alelos , Alopecia/genética , Estatura , Calcio/administración & dosificación , Preescolar , Suplementos Dietéticos , Femenino , Genoma Humano , Trastornos del Crecimiento/genética , Heterocigoto , Homocigoto , Humanos , Hidroxicolecalciferoles/administración & dosificación , Mutación , Vitamina D/metabolismoAsunto(s)
Túbulos Renales Proximales/metabolismo , Raquitismo Hipofosfatémico/metabolismo , Factor-23 de Crecimiento de Fibroblastos , Factores de Crecimiento de Fibroblastos/fisiología , Humanos , Fósforo/metabolismo , Enfermedades Raras , Raquitismo Hipofosfatémico/diagnóstico , Raquitismo Hipofosfatémico/genética , Raquitismo Hipofosfatémico/terapiaRESUMEN
Fibroblast growth factor-23 (FGF23) regulates phosphate reabsorption in the kidney and therefore plays an essential role in phosphate balance in humans. There is a host of defects that ultimately lead to excess FGF23 levels and thereby cause renal phosphate wasting and hypophosphatemic rickets. We describe the genetic, pathophysiologic, and clinical aspects of this group of disorders with a focus on X-linked hypophosphatemia (XLH), the best characterized of these abnormalities. We also discuss autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR) and tumor-induced osteomalacia (TIO) in addition to other rarer FGF23-mediated conditions. We contrast the FGF23-mediated disorders with FGF23-independent hypophosphatemia, specifically hypophosphatemic rickets with hypercalciuria (HHRH). Errant diagnosis of hypophosphatemic disorders is common. This review aims to enhance the recognition and appropriate diagnosis of hypophosphatemia and to guide appropriate treatment.
Asunto(s)
Factores de Crecimiento de Fibroblastos/fisiología , Homeostasis/fisiología , Fósforo/metabolismo , Raquitismo Hipofosfatémico/fisiopatología , Huesos/metabolismo , Calcitonina/uso terapéutico , Factor-23 de Crecimiento de Fibroblastos , Humanos , Osteomalacia/fisiopatología , Raquitismo Hipofosfatémico/diagnóstico , Raquitismo Hipofosfatémico/genéticaRESUMEN
Osteomalacia is a rare disorder of bone metabolism leading to reduced bone mineralization. Underlying vitamin D deficiency and a disturbed phosphate metabolism (so-called hypophosphatemic osteomalacia) can cause the disease. Leading symptoms are dull localized or generalized bone pain, muscle weakness and cramps as well as increased incidence of falls. Rheumatic diseases, such as polymyalgia rheumatica, rheumatoid arthritis, myositis and fibromyalgia must be considered in the differential diagnosis. Alkaline phosphatase (AP) is typically elevated in osteomalacia while serum phosphate and/or 25-OH vitamin D3 levels are reduced. The diagnosis of osteomalacia can be confirmed by an iliac crest bone biopsy. Histological correlate is reduced or deficient mineralization of the newly synthesized extracellular matrix. Treatment strategies comprise supplementation of vitamin D and calcium and for patients with intestinal malabsorption syndromes vitamin D and calcium are also given parenterally. In renal phosphate wasting syndromes substitution of phosphate is the treatment of choice, except for tumor-induced osteomalacia when removal of the tumor leads to a cure in most cases.
Asunto(s)
Densidad Ósea/fisiología , Huesos/fisiopatología , Osteoartritis/fisiopatología , Fosfatasa Alcalina/fisiología , Densidad Ósea/efectos de los fármacos , Huesos/efectos de los fármacos , Calcio/uso terapéutico , Humanos , Osteoartritis/diagnóstico , Osteoartritis/tratamiento farmacológico , Osteomalacia/diagnóstico , Osteomalacia/tratamiento farmacológico , Osteomalacia/fisiopatología , Síndromes Paraneoplásicos/diagnóstico , Síndromes Paraneoplásicos/tratamiento farmacológico , Síndromes Paraneoplásicos/fisiopatología , Raquitismo Hipofosfatémico/diagnóstico , Raquitismo Hipofosfatémico/tratamiento farmacológico , Raquitismo Hipofosfatémico/fisiopatología , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/tratamiento farmacológico , Deficiencia de Vitamina D/fisiopatologíaRESUMEN
OBJECTIVE: To present clinical and etiological profile of refractory rickets from Mumbai. METHODS: Case records of 36 patients presenting over 2½ y with refractory rickets were evaluated with respect to clinical presentation, biochemical, radiological features and where needed, ophthalmological examination, ultrasonography and special tests on blood and urine. RESULTS: Twenty three (63 %) patients had renal tubular acidosis (RTA)-distal RTA in 20 and proximal RTA in 3 patients; 5 (14 %) had vitamin D dependent rickets (VDDR I in 2 and VDDR II in 3 patients), 4 (11 %) had chronic renal failure (CRF) and 2 each (6 %) had hypophosphatemic rickets and chronic liver disease as cause of refractory rickets. A significant proportion of patients with RTA and VDDR showed skeletal changes of rickets in the first 2 y of life, while those with hypophosphatemic rickets presented later. Patients with hypophosphatemic rickets had predominant involvement of lower limbs, normal blood calcium and PTH levels and phosphorus leak in urine. All patients with RTA presented with failure to thrive, polyuria and marked rickets; blood alkaline phosphatase levels being normal in almost 50 % patients. Three (75 %) patients with rickets due to CRF had GFR < 30 ml/min/1.73 m(2) and hyperphosphatemia. Patients with cirrhosis due to biliary atresia had rickets inspite of taking high dose of vitamin D orally. CONCLUSIONS: Refractory rickets is a disorder of multiple etiologies; a good history and clinical examination supplemented with appropriate investigations helps to determine its cause.